**Supplementary Table 2.** Univariable unadjusted hazard ratios and 95% confidence intervals of covariates and a liver-related event

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Hazard ratio (HR)** | **95% Confidence Interval (CI) of HR** | ***p*-value** |
| *Histologic covariates* |  |
| Fibrosis stage0-1234 | Reference0.782.737.93 | Reference0.28-2.151.25-5.964.36-14.42 | 0.630.01<0.01 |
| Lobular inflammation0123 | Reference1.041.271.73 | Reference0.52-2.090.62-2.580.64-4.69 | 0.910.510.28 |
| Portal inflammation012 | Reference2.312.49 | Reference1.41-3.791.10-5.63 | <0.010.03 |
| Steatosis0123 | Reference0.270.180.21 | Reference0.11-0.660.08-0.450.08-0.53 | <0.01<0.01<0.01 |
| Ballooning012 | Reference2.063.02 | Reference1.24-3.441.36-6.75 | <0.01<0.01 |
| Acidophils01 | Reference0.68 | Reference0.21-2.16 | 0.51 |
| Mallory bodies012 | Reference2.25- | Reference1.35-3.75- | <0.01- |
| Microvesicular fat | 2.13 | 0.92-4.92 | 0.08 |
| NAFLD activity score | 1.05 | 0.90-1.22 | 0.53 |
| *Clinical covariates*  |  |
| Age | 1.05 | 1.03-1.07 | <0.01 |
| BMIUnderweight/NormalOverweightObese | Reference1.821.19 | Reference0.63-5.270.43-3.32 | 0.270.74 |
| GenderMaleFemale | Reference0.71 | Reference0.45-1.14 | 0.16 |
| RaceWhiteAsianBlack | Reference0.620.91 | Reference0.09-4.440.28-2.90 | 0.630.87 |
| EthnicityNon-HispanicHispanic | Reference0.89 | Reference0.50-1.57 | 0.68 |
| SmokerNever smokerFormer smokerCurrent smoker | Reference1.960.66 | Reference1.20-3.190.23-1.85 | <0.010.42 |
| Hypertension | 2.21 | 1.31-3.73 | <0.01 |
| Type 2 diabetes mellitus | 1.96 | 1.21-3.17 | <0.01 |
| Coronary artery disease | 2.58 | 1.38-4.80 | <0.01 |
| Chronic kidney disease | 2.03 | 0.97-4.24 | 0.06 |
| Congestive heart failure  | 1.86 | 0.68-5.11 | 0.23 |
| Obstructive sleep apnea | 1.07 | 0.58-1.97 | 0.83 |
| *Medications* |  |  |  |
| DPP-4 inhibitor | 3.34 | 1.05-10.64 | 0.04 |
| GLP-1 agonist | 1.66 | 0.60-4.55 | 0.33 |
| Metformin | 1.81 | 0.93-3.53 | 0.08 |
| Statin | 1.05 | 0.52-2.11 | 0.23 |